Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.6061/clinics/2021/e2342 http://scihub22266oqcxt.onion/10.6061/clinics/2021/e2342 33852652!8009081!33852652     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clinics+(Sao+Paulo) 2021 ; 76 (ä): e2342 Nephropedia Template TP {{tp|p=33852652|t=2021. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review |pdf=|usr=}}{{33852652}} gab.com Text Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review JO: Clinics (Sao Paulo) http://www.kidney.de/pget.php?&tw=1&pmid=33852652 #FOAvip Among the multiple uncertainties surrounding the novel coronavirus disease (COVID-19) pandemic, a research letter published in The Lancet implicated drugs that antagonize the renin-angiotensin-aldosterone system (RAAS) in an unfavorable prognosis of COVID-19. This report prompted investigations to identify mechanisms by which blocking angiotensin-converting enzyme 2 (ACE2) could lead to serious consequences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The possible association between RAAS inhibitors use and unfavorable prognosis in this disease may have been biased by the presence of underlying cardiovascular diseases. As the number of COVID-19 cases has increased worldwide, it has now become possible to investigate the association between RAAS inhibitors and unfavorable prognosis in larger cohorts. Observational studies and one randomized clinical trial failed to identify any consistent association between the use of these drugs and unfavorable prognosis in COVID-19. In view of the accumulated clinical evidence, several scientific societies recommend that treatment with RAAS inhibitors should not be discontinued in patients diagnosed with COVID-19 (unless contraindicated). This recommendation should be followed by clinicians and patients. Twit Text FOAVip Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review ????Clinics (Sao Paulo) http://www.kidney.de/pget.php?&tw=1&pmid=33852652 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33852652 #FOAvip English Wikipedia <ref>{{Cite pmid|33852652}}</ref> Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review #MMPMID33852652 Ferrari F; Martins VM; Fuchs FD; Stein R Clinics (Sao Paulo) 2021[]; 76 (ä): e2342 PMID33852652show ga Among the multiple uncertainties surrounding the novel coronavirus disease (COVID-19) pandemic, a research letter published in The Lancet implicated drugs that antagonize the renin-angiotensin-aldosterone system (RAAS) in an unfavorable prognosis of COVID-19. This report prompted investigations to identify mechanisms by which blocking angiotensin-converting enzyme 2 (ACE2) could lead to serious consequences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The possible association between RAAS inhibitors use and unfavorable prognosis in this disease may have been biased by the presence of underlying cardiovascular diseases. As the number of COVID-19 cases has increased worldwide, it has now become possible to investigate the association between RAAS inhibitors and unfavorable prognosis in larger cohorts. Observational studies and one randomized clinical trial failed to identify any consistent association between the use of these drugs and unfavorable prognosis in COVID-19. In view of the accumulated clinical evidence, several scientific societies recommend that treatment with RAAS inhibitors should not be discontinued in patients diagnosed with COVID-19 (unless contraindicated). This recommendation should be followed by clinicians and patients. |*COVID-19[MESH] |*Coronavirus[MESH] |Angiotensin Receptor Antagonists/adverse effects[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects[MESH] |Humans[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Randomized Controlled Trials as Topic[MESH] |Renin-Angiotensin System[MESH]Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review (epmc).pdf DeepDyve Pubget Overpricing